VivoSeq
Oncology

Tumor-Induced Osteomalacia

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Tumor-Induced Osteomalacia is an early-stage landscape with 0 programs across 2 companies. The most active players are Kyowa Kirin, Inc., Kyowa Kirin Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kyowa Kirin, Inc.

0 programs

PreclinicalKyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Terminated1 · 33%

Clinical Trials

Trial Activity

BGJ398 for the Treatment of Tumor-Induced Osteomalacia
Terminated·National Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT03510455·4 enrolled
Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)
Completed·KKyowa Kirin, Inc.·Phase 2·NCT02304367·17 enrolled
A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
Completed·Kyowa Kirin Co., Ltd. logoKyowa Kirin Co., Ltd.·Phase 2·NCT02722798·14 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)